The United States Pharmacopeial Convention (USP) has commented on the FDA draft guidance, “Nonproprietary Naming of Biological Products: Guidance for Industry”, which describes FDA’s proposal that all biologics bear a nonproprietary name that includes a manufacturer-specific FDA-designated suffix. “We understand the naming approach for biologics in the Draft Guidance reflects FDA’s interest in preventing inadvertent substitution of and facilitating pharmacovigila...